Pharma BD Deal Intelligence
A $535M bet on an unproven epigenetic platform that never produced a marketed drug — shelved by 2019, one combination trial ended early for safety without efficacy.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
BioSpace highlighted Roche's confidence in BET-inhibitor science, with Bradner-led origins at Dana-Farber and early NMC data presented at AACR/NCI/EORTC in…
Roche acquires Tensha Therapeutics for $115 million upfront and up to $420 million in milestones, gaining the BET inhibitor TEN-010 in two Phase Ib trials.
Pharmafile framed Roche as 'a leader and early adopter of innovation,' positioning the deal as strategically significant for advancing BET-targeted…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Roche acquired Cambridge, MA-based Tensha Therapeutics for $115M upfront plus up to $420M in clinical/regulatory milestones. Founded by James Bradner of Dana-Farber, Tensha developed BET-protein inhibitor TEN-010 in Phase 1b for NMC, AML, and MDS. Adds to Roche's epigenetics portfolio.
A $535M bet on an unproven epigenetic platform that never produced a marketed drug — shelved by 2019, one combination trial ended early for safety without efficacy.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| F. Hoffmann-La Roche AG / Tensha Therapeutics, Inc. (this deal) | 2016 | $535M | 20 |
| F. Hoffmann-La Roche AG / Manifold Bio, Inc. | 2025 | $2.0B | — |
| F. Hoffmann-La Roche AG / Qyuns Therapeutics Co., Ltd. | 2025 | $1.1B | — |
| F. Hoffmann-La Roche AG / Ionis Pharmaceuticals, Inc. | 2023 | $760M | — |
| F. Hoffmann-La Roche AG / MediLink Therapeutics (Suzhou) Co., Ltd. | 2026 | $570M | — |
| F. Hoffmann-La Roche AG / Hansoh Pharmaceutical Group Co. Ltd. | 2025 | $1.5B | — |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
← Browse all deals · How we score deals
More: 2016 deals · F. Hoffmann-La Roche AG deals · Hematology deals